PT-141 (Bremelanotide): mechanisms, research and complete pharmacological profile
A synthetic derivative of α-MSH, PT-141 (Bremelanotide) is the only melanocortin MC3R/MC4R receptor activating peptide to have received FDA approval. This article reviews its mechanisms of action, clinical data, and research profile.
What is the PT-141?
Le PT-141, Or Bremelanotide, is a cyclic heptapeptide (7 amino acids) with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OHIt was developed from Melanotan II, itself an analogue of the melanotropic hormone α-MSH (alpha-melanocyte-stimulating hormone).
Unlike Melanotan II, which acts on several melanocortin receptors (MC1R to MC5R), PT-141 presents a increased selectivity for MC3R and MC4R receptors, located primarily in the central nervous system.
Mechanisms of action
central melanocortin system
The PT-141 acts as MC3R and MC4R receptor agonist in the hypothalamus and limbic system. These receptors are part of the melanocortin system, a neuroendocrine network involved in the regulation of appetite, energy metabolism and sexual behavior.
- Direct activation of the hypothalamic MC4R, triggering a signaling cascade via Gαs proteins
- Increase in intracellular cAMP in paraventricular nucleus neurons
- Downward modulation of oxytocinergic and dopaminergic pathways to spinal centers
- Central action (and not peripheral vascular action), which distinguishes PT-141 from PDE5 inhibitors
Interaction with the dopaminergic system
Preclinical studies show that activation of MC4R by PT-141 stimulates the release of dopamine in the medial preoptic area (mPOA), a key region for motivational behavior. This MC4R → dopamine pathway explains the central mechanism of action of the peptide.
Oxytocinergic pathway
PT-141 also activates oxytocinergic neurons in the paraventricular nucleus (PVN), which project to the sacral spinal cord. This pathway oxytocin-spinal is documented as a mediator of the physiological effects observed in animal models.
Research data
Preclinical studies
Studies on animal models have established that PT-141:
- Activates MC4R receptors with an EC50 on the order of nanomolar
- Induces dose-dependent behavioral responses in rats
- Maintains its effectiveness after repeated administrations (low tachyphylaxis)
- Does not significantly affect blood pressure at active doses (unlike Melanotan II)
Clinical data
Bremelanotide has been the subject of phase III clinical programs (RECONNECT studies) which led to FDA approval in 2019 under the trade name Vyleesi®:
| Study | Population | Main result |
|---|---|---|
| RECONNECT-1 (Phase III) | n=634 | Significant improvement in FSFI-D score vs placebo (p<0.001) |
| RECONNECT-2 (Phase III) | n=631 | Reduction in FSDS-R distress score (p<0.001) |
| 12-month extension study | n=272 | Maintaining efficiency, stable safety profile |
Pharmacological profile
| Setting | Value |
|---|---|
| Molecular mass | 1,025.2 Da |
| Half-life | ~2.7 hours |
| Tmax | ~1 hour (SC route) |
| SC Bioavailability | ~100% |
| Metabolism | Peptide hydrolysis |
| Elimination | Renal (64.8%) |
Documented side effects
Clinical trials have reported the following effects:
- Nausea (40%) — the most frequent effect, generally transient
- Facial flush (20%)
- Headaches (11%)
- Possible transient hyperpigmentation (linked to residual MC1R activity)
- Transient elevation of blood pressure within 12 hours post-injection
PT-141 should not be combined with antihypertensive drugs in experimental protocols due to documented transient blood pressure elevation.
PT-141 vs Melanotan II
| Characteristic | PT-141 | Melanotan II |
|---|---|---|
| Structure | Cyclic heptapeptide | Cyclic heptapeptide |
| Receiver selectivity | MC3R/MC4R | MC1R-MC5R (non-selective) |
| Pigmentation | Minimal | Significant (MC1R) |
| Appetite effect | Weak | Marked anorexigenic |
| Regulatory status | FDA approved (Vyleesi) | Not approved |
| Half-life | ~2.7h | ~2h |
Applications in laboratory research
In a scientific research context, PT-141 is studied for:
- Investigation of central melanocortin pathways (MC3R/MC4R)
- Models for studying hypothalamic signaling
- Research on the interaction between melanocortin, dopamine, and oxytocin
- Comparative studies with next-generation MC4R agonists
- Models of motivational behavior regulation
PT-141 certified HPLC 99%+ available
MyPeptide offers the PT-141 research sample with Janoshik certificate of analysis. Shipping from the European Union in 48-72 hours.
🧪 Research Peptides — Europe Delivery
≥99% Purity HPLC certified by Janoshik · COA available per batch · Discreet shipping 48-72h
🇫🇷 Retarturate France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
🇮🇹 Italy
🇫🇷 GHK-Cu France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
→ All countries
📚 Scientific reference:
Diamond LE et al. “A double-blind, placebo-controlled evaluation of PT-141. » J Sex Med. 2004.
PubMed PMID:16422897 →